Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia.
Data on the use of long-acting injectable (LAI) risperidone, the first atypical depot antipsychotic, during pregnancy are limited. A 35-year-old woman with schizophrenia was given LAI risperidone before and throughout her pregnancy. She gave birth to a female infant weighing 2230 g at 36 weeks and 6 days of pregnancy, following premature rupture of the membranes. The baby had no congenital malformation and was healthy 8 months postnatal. To our knowledge, this is the first reported use of LAI risperidone throughout an entire pregnancy. In this paper, we discuss the rationale and problems of LAI risperidone use in pregnancy, based on a literature review.
Kim
Sung-Wan
SW
Department of Psychiatry, Chonnam National University Medical School, 5 Hak-dong, Dong-ku, Kwangju 501-746, Republic of Korea.
Kim
Ki-Min
KM
Kim
Jae-Min
JM
Shin
Il-Seon
IS
Shin
Hee-Young
HY
Yang
Su-Jin
SJ
Yoon
Jin-Sang
JS
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007267:Injections / Q000379:methods; D011247:Pregnancy; D018967:Risperidone / Q000008:administration & dosage*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D018967:Risperidone